No Perinatal HIV-1 Transmission From Women With Effective Antiretroviral Therapy Starting Before Conception
No Perinatal HIV-1 Transmission From Women With Effective Antiretroviral Therapy Starting Before Conception
复制标题
DOI：
10.1093/cid/civ578
复制
发表时间：
2015-12-01
影响因子：
11.8
通讯作者：
Blanche, Stephane
中科院分区：
文献类型：
--
作者：
Mandelbrot, Laurent;Tubiana, Roland;Blanche, Stephane
背景预防人类免疫缺陷病毒1型（HIV-1）围产期传播（PT）的有效性取决于病毒载量（VL）和治疗持续时间。本研究的目的是确定是否启动高活性抗逆转录病毒治疗（ART）在怀孕前有可能消除PT。2000年至2011年，国家前瞻性多中心法国围产期队列（ANRS-EPF）中共有8075对艾滋病毒感染的母亲/婴儿接受了抗逆转录病毒治疗，分娩了确定为艾滋病毒感染状态的活产婴儿，并且没有母乳喂养。根据分娩时母亲的VL和ART启动时间分析PT。结果。PT的总体发生率为0.7%（56/8075）。在怀孕前接受抗逆转录病毒治疗的妇女所生的2651名婴儿中，没有发生传播，在整个怀孕期间继续接受抗逆转录病毒治疗，并在分娩时血浆VL
Background. The efficacy of preventing perinatal transmission (PT) of human immunodeficiency virus type 1 (HIV-1) depends on both viral load (VL) and treatment duration. The objective of this study was to determine whether initiating highly active antiretroviral therapy (ART) before conception has the potential to eliminate PT.Methods. A total of 8075 HIV-infected mother/infant pairs included from 2000 to 2011 in the national prospective multicenter French Perinatal Cohort (ANRS-EPF) received ART, delivered live-born children with determined HIV infection status, and did not breastfeed. PT was analyzed according to maternal VL at delivery and timing of ART initiation.Results. The overall rate of PT was 0.7% (56 of 8075). No transmission occurred among 2651 infants born to women who were receiving ART before conception, continued ART throughout the pregnancy, and delivered with a plasma VL